MONTREAL, QUEBEC, CANADA--(Marketwire - November 13, 2008) - Theratechnologies (TSX: TH) announced that the last patient has completed 52 weeks of treatment in the extension phase of the confirmatory Phase 3 trial testing tesamorelin in HIV-associated lipodystrophy. The Company now expects to be in a position to present top-line 52-week results of this confirmatory Phase 3 trial by year end.
